<DOC>
	<DOCNO>NCT00854880</DOCNO>
	<brief_summary>The objective trial evaluate efficacy safety PDC-339 treatment acute erosive gastritis , use placebo comparator .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Efficacy Safety PDC-339 Treatment Acute Erosive Gastritis</brief_title>
	<detailed_description>The primary biologically active component ginseng saponin triterpenoid glycoside call ginsenosides whose name relate chromatographic position ( Ra , Rb , etc. ) . Based related study , American ginseng infer effect modulate gastrointestinal system , lower blood sugar level , enhance memory , suppress mutation breast cancer cell line . It also anti-oxidant neuroprotective effect . Among experience therapeutic us American ginseng , conclude American ginseng effective treat gastrointestinal disease . PDC339 active ingredient American ginseng . This randomized , double blind , placebo-controlled parallel comparative phase II clinical trial evaluate efficacy safety PDC-339 patient acute erosive gastritis . The study period patient include screening/wash-out period 1 week treatment period ( include 2-week follow-up ) 6 week . Subjects require make total 5 visit . There total evaluable 60 patient ( 20 patient treatment group ) . If drop rate assume 10 % , total 69 eligible patient . All subject meet inclusion exclusion criterion enrol study receive randomly either PDC-339 placebo accord randomization list . The following clinical assessment perform : Primary efficacy assessment - change endoscopic gastric integrity ; secondary efficacy assessment - change severity symptom 4-point scale visit 3,4 baseline .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 . Patients &gt; 20 year old , male female ; 2 . Patients endoscopybased evidence ( Lanza Score â‰§ 2 ) untreated acute erosive gastritis examination ; 3 . Having negative result fecal occult blood test hemoglobin normal range 2 g/dL ; 4 . Patients voluntarily sign write informed consent may participate study . 1 . Pregnant lactate female ; * 2 . Patients endoscopybased evidence gastric malignancy , pyloric obstruction , esophageal stricture require dilation , fresh clot , active bleeding , perforated ulcer ; 3 . Use proton pump inhibitor , sucralfate , H2receptor antagonist , bismuth preparation within 1 week initiate study drug therapy ; 4 . Patients require anticoagulant corticosteroid therapy ( dosage great equivalent prednisone , 10 mg/day ) ; 5 . Patients significant impairment renal function ( creatinine &gt; 2mg/dl ) ; liver function impairment ( AST ALT 2x upper limit normal ) ; severe cardiac disease , e.g . angina pectoris , myocardial infarction , cardiac arrhythmia , congestive heart failure ( New York Heart Association Functional Classification III IV ) acute respiratory disease ; 6 . Any peptic ulcer uppergastrointestinal endoscopy ; 7 . Patients history esophageal and/or gastric varix ; 8 . Known hypersensitivity American ginseng ; 9 . Use investigational drug within 30 day prior study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Erosive Gastritis</keyword>
</DOC>